Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma

International Journal of Gynecological Pathology

Volumn 17, Issue 2, 1998, Pages 135-139

  Kuwashima, Yoshio ^a   Kurosumi, Masafumi ^a   Kobayashi, Yasuhito ^a   Tanuma, Junichi ^b   Suemasu, Kimito ^a   Higashi, Yasuhiro ^a   Kasamatsu, Takahiro ^a   Shiromizu, Kenji ^a   Kishi, Kiyozo ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

bcl 2; Breast cancer; Endometrial carcinoma; p53; Tamoxifen

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DNA ADDUCT; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0031899944     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199804000-00007     Document Type: Article

References (44)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
3. Greenblat MS, Bennet WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene; clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
4. Scheffner M, Werness BA, Huibregte JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
5. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990; 248:76-9.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
7. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
8. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
9. Wastra WH, Offerhaus JA, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17:213-20.
10. Vahakangas K, Pelkonen O. Host variations in carcinogen metabolism and DNA repair. In: Lynch HT, Hirayama T (eds). Genetic Epidemiology of Cancer. Boca Raton, FL: CRC Press,:35-54.
11. Ramet M, Castren K, Jarvinen K, et al. p53 protein expression is correlated with Benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 1995;16:2117-24.
12. Denissenko MF, Pao A, Tang M-S, Pfeifer GP. Preferential formation of Benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-2.
13. Curigliano G, Zhang Y-J, Wang, L-Y, et al. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 1996;17:911-6.
14. Bass IO, Muldder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistory of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
15. Umekita Y, Kobayashi K, Saheki T, Yoshida H. Nuclear accumulation of p53 protein correlate with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn J Cancer Res 1994;85:825-30.
16. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52: 1622-7.
17. Cancer Research Campaign Breast Cancer Trials Group. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur J Cancer 1992;28A:904-7.
18. Pasqualini JR, Sumida C, Giambiagi N. Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem 1988;31:613-43.
19. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with 2 antiestrogens. Arch Toxicol 1993;67:49-54.
20. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wister-derived rats. Cancer Res 1993;53:3919-24.
21. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993;14:315-7.
22. Carthew P, Martin EA, White INH, et al. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rat: promotion by phenobarbital. Cancer Res 1995;55:544-7.
23. Carthew P, Rich KJ, Martin EA, et al. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis 1995 16:1299-304.
24. Wang M-Y, Liehr JG. Induction by estrogens of lipid peroxidation and lipid peroxide-derived malonaldehyde-DNA adducts in male syrian hamsters: role of lipid peroxidation in estrogen-induced kidney carcinogenesis. Carcinogenesis 1995;16:1941-5.
25. Hayashi N, Hasegawa K, Komine A, et al. Estrogen-induced cell transformation and DNA adduct formation in cultured syrian hamster embryo cells. Mol Carcinogenesis 1996;16:149-56.
26. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
27. Friedl A, Jordan VC. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994;31:27-39.
28. Lanza A, Alba E, Re A, et al. Endometrial carcinoma in breast cancer patients treated with tamoxifen. two case report and review of the literature. Eur J Gynaecol Oncol 1994;15:455-9.
29. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
30. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33.
31. Kuwashima Y, Kurosumi M, Kobayashi Y, et al. Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note. Anticancer Res 1996;16: 2993-6.
32. Carmichael PL, Ugwumadu AHN, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996;56:1475-9.
33. Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996;56:4374-7.
34. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994;54:3864-7.
35. Wang Y, Szekely L, Okan I, Klein G, Wiman K. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993;8:3427-31.
36. Chiou S-K, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994;14:2556-63.
37. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxydase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
38. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101:183-9.
39. Kuwashima Y, Uehara T, Kishi K, Shiromizu K, Matsuzawa M, Takayama S. Proliferative and apoptotic status in endometrial adenocarcinoma. Int J Gynecol Pathol 1995;14:45-9.
40. Anonymous Announcements. FIGO stage - 1988 revision. Gynecol Oncol 1989;35:125-7.
41. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98: 81-7.
42. Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-10.
43. Ambros RA, Vigna PA, Figge J, et al. Observation on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73:1686-92.
44. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-6.